GE Healthcare wins FDA clearance for Alzheimer’s imaging software
The clearance adds a Centiloid scale tool to GE Healthcare’s Mim software to help clinicians determine the density of amyloid ...
STAT4d
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
Goldman Sachs Remains a Hold on Novartis AG (NOVN)
Goldman Sachs analyst James Quigley maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
cnbctv184d
USFDA approves Novartis' Kisqali for early-stage breast cancer treatment
This approval marks a breakthrough for individuals diagnosed with hormone receptor-positive (HR+)/HER2-negative stage II and ...
kalkinemedia4d
How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market
As weight-loss treatments dominate the pharmaceutical market, Swiss drugmaker Novartis AG (SWX: NOVN) is choosing a different ...
Benzinga on MSN4d
Novartis Skips Weight Loss Drug 'Frenzy,' Focuses on 'Unique Position' for Cancer, Alzheimers, and Parkinsons Treatments
Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated ...
Novartis: Kisqali Reduces Recurrence Risk By 28.5% In Late-stage Early Breast Cancer Trial
Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III ...
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
BioWorld4d
Novartis synthesizes fast-acting intravenous agents for malaria
The increasing resistance to intravenous artemisinin therapy for malaria highlights the urgent need for new treatments that offer better patient compliance and a single-dose cure to address this ...